|
Pharmaceutical firm reports loss of $0.08 per share.
Publication: Obesity, Fitness & Wellness Week Publication Date: 18-SEP-04 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2004 NewsRX
2004 SEP 18 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals (AVN) reported a net loss for the third quarter of fiscal 2004 of $6.6 million, or $0.08 per share, compared with a net loss of $6.0 million, or $0.10 per share for the same period a year ago.
Total operating expenses were $7.3 million in the third fiscal quarter of 2004, compared to $6.4 million in the same period in fiscal 2003. Research and development (R&D) expenses were $5.1 million in the third fiscal quarter of 2004, compared to $4.5 million in the same period a year ago.
Research and development programs accounted for 70%...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Obesity, Fitness & Wellness Week |
Data describe selectivity, efficacy, lack of toxicity of oncolytic ade...
September 18, 2004
|
Culture systems improve the study of gene function in inaccessible tis...
September 18, 2004
|
Pyridinium cationic lipids surpass the efforts of classic DTOAP-based ...
September 18, 2004
|
Temperature and pH responsive polymers react to environmental changes.
September 18, 2004
|
Biopharmaceutical company announces new gene trapping patent.
September 18, 2004
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
